For over 22 years, Wall Street elites have kept this little-known "income hack" from everyday investors… 6 simple clicks have set up HUGE payouts for "in-the-know" investors… Delivering them passive income 365 days a year.

Just click here now to watch my presentation for free.

OLMA Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 23.50%

Insider Buying (Last 12 Months): $17,849,606.18

Insider Selling (Last 12 Months): $3,307,242.47

Olema Pharmaceuticals Insider Trading History Chart

Olema Pharmaceuticals Share Price & Price History

^$10.67

▲ +0.6 (5.96%)

As of 05/3/2024 01:00 AM ET

Days: 30 | 90 | 365

Elon to Transform U.S. Economy?

From Porter & Company | Ad

A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.

One company holds a near-total monopoly on it.

Olema Pharmaceuticals Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/30/2024	Cyrus Harmon	Director	Sell	15,000	$9.51	$142,650.00	811,283
3/28/2024	Cyrus Harmon	Director	Sell	20,000	$10.97	$219,400.00	826,283
2/29/2024	Cyrus Harmon	Director	Sell	25,000	$12.41	$310,250.00	846,283
1/31/2024	Cyrus Harmon	Director	Sell	25,000	$12.23	$305,750.00	876,283
12/6/2023	Biocapital Advisors L Paradigm	Major Shareholder	Buy	100,000	$11.60	$1,160,000.00	6,590,981
12/5/2023	G. Walmsley Graham	Director	Buy	131,870	$14.19	$1,871,235.30	1,800,000
11/30/2023	Cyrus Harmon	Director	Sell	25,000	$12.57	$314,250.00	926,283
11/21/2023	Cyrus Harmon	Director	Sell	4,192	$14.86	$62,293.12	955,272
11/21/2023	Naseem Zojwalla	Insider	Sell	7,461	$14.84	$110,721.24	37,759
11/21/2023	Sean Bohen	CEO	Sell	29,293	$14.88	$435,879.84	172,857
11/8/2023	David C Myles	Insider	Sell	200	$17.61	$3,522.00	561,270
11/3/2023	David C Myles	Insider	Sell	541	$17.51	$9,472.91	561,470
11/2/2023	Cyrus Harmon	Director	Sell	5,000	$15.64	$78,200.00	943,714
11/1/2023	David C Myles	Insider	Sell	6,668	$15.02	$100,153.36	565,343
10/31/2023	Cyrus Harmon	Director	Sell	25,000	$12.05	$301,250.00	948,714
9/29/2023	Cyrus Harmon	Director	Sell	25,000	$12.41	$310,250.00	973,714
9/19/2023	David C Myles	Insider	Sell	20,000	$12.67	$253,400.00	572,011
9/12/2023	Bvf Partners L P/Il	Director	Buy	1,505,932	$9.84	$14,818,370.88	4,688,954
9/5/2023	Cyrus Harmon	Director	Sell	10,000	$11.62	$116,200.00	998,714
8/31/2023	Cyrus Harmon	Director	Sell	15,000	$9.36	$140,400.00	1,008,714
6/8/2023	Cyrus Harmon	Director	Sell	10,000	$6.30	$63,000.00	1,038,714
6/5/2023	Cyrus Harmon	Director	Sell	5,000	$6.04	$30,200.00	1,053,714
6/10/2022	Bvf Partners L P/Il	Director	Buy	200,000	$4.03	$806,000.00	3,913,676
3/10/2022	Kinney Horn	Insider	Sell	5,253	$4.75	$24,951.75
1/10/2022	Kinney Horn	Insider	Sell	5,251	$6.85	$35,969.35
12/10/2021	Kinney Horn	Insider	Sell	5,251	$10.39	$54,557.89
11/30/2021	Bvf Partners L P/Il	Director	Buy	739,675	$9.39	$6,945,548.25
11/29/2021	Cyrus Harmon	CTO	Sell	400	$24.76	$9,904.00
10/19/2021	Cyrus Harmon	CTO	Sell	12,000	$27.98	$335,760.00
10/14/2021	Sean Bohen	CEO	Sell	5,000	$30.47	$152,350.00
10/11/2021	Kinney Horn	Insider	Sell	5,251	$27.90	$146,502.90
9/27/2021	Sean Bohen	CEO	Sell	1,085	$30.07	$32,625.95
9/20/2021	Cyrus Harmon	CTO	Sell	12,000	$26.30	$315,600.00
9/10/2021	Kinney Horn	Insider	Sell	5,251	$29.38	$154,274.38
9/1/2021	Sean Bohen	CEO	Sell	871	$30.05	$26,173.55
8/19/2021	Cyrus Harmon	CTO	Sell	12,000	$24.97	$299,640.00	1,075,546
8/10/2021	Kinney Horn	Insider	Sell	5,251	$25.71	$135,003.21	7,041
7/20/2021	Cyrus Harmon	CTO	Sell	4,123	$25.63	$105,672.49
7/12/2021	Kinney Horn	Insider	Sell	5,251	$26.51	$139,204.01	7,041
6/18/2021	Cyrus Harmon	CTO	Sell	12,000	$24.80	$297,600.00	1,102,136
6/10/2021	Kinney Horn	Insider	Sell	5,251	$29.72	$156,059.72	7,041
5/18/2021	Kinney Horn	Insider	Sell	57,763	$24.15	$1,394,976.45

Elon to Transform U.S. Economy?

From Porter & Company | Ad

One company holds a near-total monopoly on it.

SEC Filings (Institutional Ownership Changes) for Olema Pharmaceuticals (NASDAQ:OLMA)

91.78% of Olema Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Olema Pharmaceuticals Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
5/1/2024	Mirae Asset Global Investments Co. Ltd.	10,539	$0.12M	0.0%	-33.9%	0.019%
4/29/2024	China Universal Asset Management Co. Ltd.	10,562	$0.12M	0.0%	+66.6%	0.019%
2/26/2024	Perceptive Advisors LLC	539,831	$7.57M	0.2%	N/A	0.980%
2/14/2024	First Light Asset Management LLC	631,064	$8.85M	0.7%	N/A	1.145%
2/14/2024	Sectoral Asset Management Inc.	19,230	$0.27M	0.1%	-95.6%	0.035%
2/7/2024	Dimensional Fund Advisors LP	1,715,420	$24.07M	0.0%	+1.3%	3.113%
2/7/2024	Jump Financial LLC	19,866	$0.28M	0.0%	N/A	0.036%
2/6/2024	Swiss National Bank	64,600	$0.91M	0.0%	N/A	0.117%
2/5/2024	Victory Capital Management Inc.	621,527	$8.72M	0.0%	+879.6%	1.128%
1/30/2024	Zurcher Kantonalbank Zurich Cantonalbank	9,282	$0.13M	0.0%	N/A	0.017%
1/24/2024	Mirae Asset Global Investments Co. Ltd.	15,951	$0.22M	0.0%	+9.4%	0.029%
1/24/2024	China Universal Asset Management Co. Ltd.	6,341	$89K	0.0%	N/A	0.012%
1/12/2024	SG Americas Securities LLC	15,874	$0.22M	0.0%	+38.1%	0.029%
12/19/2023	Public Employees Retirement System of Ohio	2,850	$35K	0.0%	N/A	0.005%
12/18/2023	Vanguard Group Inc.	1,710,307	$21.12M	0.0%	+2.2%	3.123%
12/1/2023	Wellington Management Group LLP	99,121	$1.22M	0.0%	+62.2%	0.181%
11/24/2023	EP Wealth Advisors LLC	46,248	$0.57M	0.0%	+831.1%	0.084%
11/22/2023	Polar Capital Holdings Plc	750,000	$9.26M	0.1%	N/A	1.369%
11/15/2023	GSA Capital Partners LLP	59,773	$0.74M	0.1%	-41.3%	0.145%
11/15/2023	Sectoral Asset Management Inc.	437,652	$5.41M	1.1%	-32.5%	1.058%
11/15/2023	Kynam Capital Management LP	235,176	$2.90M	0.5%	-82.0%	0.569%
11/15/2023	Acuta Capital Partners LLC	153,007	$1.89M	1.3%	+44.6%	0.370%
11/15/2023	Adage Capital Partners GP L.L.C.	388,982	$4.80M	0.0%	+68.1%	0.941%
11/14/2023	MPM Bioimpact LLC	1,857,681	$22.94M	6.1%	+301.7%	4.493%
11/14/2023	Schonfeld Strategic Advisors LLC	72,369	$0.89M	0.0%	-42.4%	0.175%
11/14/2023	Newtyn Management LLC	150,000	$1.85M	0.5%	-14.3%	0.363%
11/14/2023	Caxton Associates LP	13,474	$0.17M	0.0%	N/A	0.033%
11/13/2023	Algert Global LLC	47,630	$0.59M	0.0%	-18.0%	0.115%
11/13/2023	EAM Investors LLC	243,290	$3.01M	0.6%	+43.3%	0.588%
11/13/2023	Acadian Asset Management LLC	492,881	$6.09M	0.0%	-14.9%	1.192%
11/13/2023	ClariVest Asset Management LLC	65,900	$0.81M	0.0%	+23.9%	0.159%
11/13/2023	Silverarc Capital Management LLC	407,801	$5.04M	1.5%	+4.4%	0.986%
11/8/2023	Vivo Capital LLC	1,873,704	$23.14M	2.9%	+39.9%	4.531%
11/7/2023	New York State Common Retirement Fund	6,590	$81K	0.0%	-45.5%	0.016%
11/7/2023	Barclays PLC	4,657	$57K	0.0%	-13.0%	0.011%
11/6/2023	Victory Capital Management Inc.	63,450	$0.78M	0.0%	N/A	0.153%
10/24/2023	Raymond James Financial Services Advisors Inc.	13,287	$0.16M	0.0%	N/A	0.032%
10/24/2023	Raymond James & Associates	30,000	$0.37M	0.0%	N/A	0.073%
10/13/2023	SG Americas Securities LLC	11,495	$0.14M	0.0%	N/A	0.028%
10/11/2023	Vontobel Holding Ltd.	164,282	$2.03M	0.0%	-28.3%	0.397%
8/15/2023	Silverarc Capital Management LLC	390,466	$3.53M	1.1%	N/A	0.944%
8/15/2023	HighVista Strategies LLC	292,276	$2.64M	1.2%	N/A	0.707%
8/15/2023	Kynam Capital Management LP	1,304,332	$11.78M	1.6%	-35.2%	3.154%
8/14/2023	Driehaus Capital Management LLC	86,625	$0.78M	0.0%	N/A	0.209%
8/11/2023	Pale Fire Capital SE	44,000	$0.40M	0.0%	N/A	0.108%
8/11/2023	Sectoral Asset Management Inc.	648,353	$5.86M	1.0%	-34.9%	1.591%
8/8/2023	Monaco Asset Management SAM	11,809	$0.11M	0.0%	-94.7%	0.029%
8/7/2023	Acadian Asset Management LLC	579,309	$5.23M	0.0%	+0.6%	1.421%
8/4/2023	American International Group Inc.	12,922	$0.12M	0.0%	N/A	0.032%
7/24/2023	Vontobel Holding Ltd.	229,227	$2.07M	0.0%	-32.2%	0.562%
6/5/2023	EP Wealth Advisors LLC	4,508	$0.84M	0.0%	N/A	0.011%
6/1/2023	Prelude Capital Management LLC	16,225	$56K	0.0%	-18.7%	0.040%
5/12/2023	Sectoral Asset Management Inc.	995,909	$3.46M	0.7%	-30.9%	2.447%
5/9/2023	Tower Research Capital LLC TRC	29,150	$0.10M	0.0%	+197.7%	0.072%
5/1/2023	Virtu Financial LLC	10,015	$35K	0.0%	-25.9%	0.025%
4/12/2023	Vontobel Holding Ltd.	337,917	$1.17M	0.0%	-35.9%	0.832%
2/13/2023	GSA Capital Partners LLP	231,633	$0.57M	0.1%	+122.5%	0.572%
2/10/2023	New York Life Investment Management LLC	133,157	$0.33M	0.0%	+12.7%	0.329%
2/10/2023	Sectoral Asset Management Inc.	1,441,805	$3.53M	0.7%	+63.3%	3.564%
2/8/2023	Russell Investments Group Ltd.	11,991	$29K	0.0%	-44.5%	0.030%
2/3/2023	Monaco Asset Management SAM	351,517	$0.86M	0.2%	+89.7%	0.869%
1/31/2023	Monaco Asset Management SAM	351,517	$0.86M	0.3%	+89.7%	0.869%
11/15/2022	Kynam Capital Management LP	1,399,633	$3.86M	0.8%	+461.6%	3.459%
11/14/2022	Tudor Investment Corp Et Al	19,876	$55K	0.0%	N/A	0.049%
11/14/2022	PDT Partners LLC	36,541	$0.10M	0.0%	-60.4%	0.090%
11/9/2022	Fairmount Funds Management LLC	1,231,566	$3.40M	0.6%	-53.9%	3.047%
11/4/2022	Russell Investments Group Ltd.	21,588	$59K	0.0%	N/A	0.053%
10/31/2022	Monaco Asset Management SAM	185,271	$0.51M	0.2%	+42.5%	0.458%
8/15/2022	Laurion Capital Management LP	495,300	$2.02M	0.0%	N/A	1.225%
8/11/2022	Deutsche Bank AG	456,666	$1.86M	0.0%	+709.2%	1.132%
8/1/2022	Monaco Asset Management SAM	130,000	$0.53M	0.2%	N/A	0.322%
7/27/2022	Bailard Inc.	22,400	$91K	0.0%	N/A	0.056%
5/17/2022	RA Capital Management L.P.	504,505	$2.15M	0.0%	-76.5%	1.250%
5/17/2022	Fairmount Funds Management LLC	2,669,300	$11.37M	2.7%	N/A	6.615%
5/13/2022	Kynam Capital Management LP	280,827	$1.20M	0.4%	-4.4%	0.696%
5/12/2022	Running Point Capital Advisors LLC	10,000	$43K	0.0%	N/A	0.025%
5/11/2022	GSA Capital Partners LLP	72,287	$0.31M	0.0%	+79.7%	0.179%
5/6/2022	IndexIQ Advisors LLC	90,750	$0.39M	0.0%	N/A	0.225%
5/2/2022	Allspring Global Investments Holdings LLC	37,819	$0.16M	0.0%	N/A	0.094%
4/29/2022	Nisa Investment Advisors LLC	31,400	$0.13M	0.0%	N/A	0.078%
3/3/2022	Walleye Capital LLC	190,523	$1.78M	0.0%	N/A	0.473%
2/25/2022	EDBI Pte Ltd	3,181	$30K	0.0%	N/A	0.008%
2/14/2022	PDT Partners LLC	25,169	$0.24M	0.0%	N/A	0.062%
2/14/2022	Virtus ETF Advisers LLC	18,150	$0.17M	0.1%	+155.1%	0.045%
2/14/2022	GSA Capital Partners LLP	40,227	$0.38M	0.0%	N/A	0.100%
2/10/2022	Candriam Luxembourg S.C.A.	332,572	$3.11M	0.0%	-2.9%	0.825%
2/10/2022	Acadian Asset Management LLC	100,622	$0.94M	0.0%	N/A	0.250%
2/8/2022	Swiss National Bank	21,800	$0.20M	0.0%	N/A	0.054%
2/8/2022	ProShare Advisors LLC	11,173	$0.11M	0.0%	N/A	0.028%
2/8/2022	Northern Trust Corp	251,108	$2.35M	0.0%	+2.0%	0.623%
2/2/2022	New York State Common Retirement Fund	17,807	$0.17M	0.0%	+38.9%	0.044%
2/1/2022	Zurcher Kantonalbank Zurich Cantonalbank	5,655	$53K	0.0%	N/A	0.014%
1/31/2022	Dupont Capital Management Corp	18,451	$0.17M	0.0%	N/A	0.046%
1/24/2022	Strs Ohio	4,000	$37K	0.0%	+90.5%	0.010%
11/17/2021	ArrowMark Colorado Holdings LLC	610,194	$16.82M	0.1%	+108.7%	1.515%
11/16/2021	Janus Henderson Group PLC	2,475,830	$68.22M	0.0%	-23.2%	6.145%
11/16/2021	Two Sigma Investments LP	99,500	$2.74M	0.0%	N/A	0.252%
11/16/2021	Wellington Management Group LLP	1,649,204	$45.45M	0.0%	+2.0%	4.169%
11/16/2021	Metropolitan Life Insurance Co NY	7,243	$0.20M	0.0%	+57.0%	0.018%
11/16/2021	Citadel Advisors LLC	1,477,055	$40.71M	0.0%	+2.8%	3.734%

Data available starting January 2016

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

Today's Range

Now: $10.67

$10.18

$10.84

50 Day Range

MA: $11.54

$9.83

$14.80

52 Week Range

Now: $10.67

$5.02

$17.79

Volume

697,676 shs

Average Volume

781,624 shs

Market Capitalization

$596.77 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.1

Who are the company insiders with the largest holdings of Olema Pharmaceuticals?: Olema Pharmaceuticals' top insider investors include:
Biocapital Advisors L Paradigm (Major Shareholder)
Bvf Partners L P/Il (Director)
G Walmsley Graham (Director)
Cyrus Harmon (Director)
David C Myles (Insider)
Sean Bohen (CEO)
Naseem Zojwalla (Insider)
Learn More about top insider investors at Olema Pharmaceuticals.
Who are the major institutional investors of Olema Pharmaceuticals?: Olema Pharmaceuticals' top institutional shareholders include:
China Universal Asset Management Co. Ltd. — 0.02%
Mirae Asset Global Investments Co. Ltd. — 0.02%
Learn More about top institutional investors of Olema Pharmaceuticals stock.
Which major investors are selling Olema Pharmaceuticals stock?: During the previous quarter, OLMA stock was sold by these institutional investors:
Mirae Asset Global Investments Co. Ltd.
Within the last year, company insiders that have sold Olema Pharmaceuticals company stock include:
Biocapital Advisors L Paradigm (Major Shareholder)
Bvf Partners L P/Il (Director)
G Walmsley Graham (Director)
Cyrus Harmon (Director)
Learn More investors selling Olema Pharmaceuticals stock.
Which major investors are buying Olema Pharmaceuticals stock?: In the previous quarter, OLMA stock was acquired by institutional investors including:
China Universal Asset Management Co. Ltd.
Within the previous year, these company insiders have bought Olema Pharmaceuticals stock:
Biocapital Advisors L Paradigm (Major Shareholder)
Bvf Partners L P/Il (Director)
G Walmsley Graham (Director)
Learn More investors buying Olema Pharmaceuticals stock.

Automatic Income (from home)

From Awesomely, LLC | Ad